Who makes Naloxone and Docusate?

Naloxone and Docusate is developed by CAMC Health System.

What development phase is Naloxone and Docusate in?

Naloxone and Docusate is FDA-approved (marketed).

What are the side effects of Naloxone and Docusate?

Common side effects include Withdrawal symptoms (naloxone), Abdominal cramping (docusate), Diarrhea (docusate), Nausea.

Last reviewed 2026-04-22 · How we verify

Naloxone and Docusate

CAMC Health System · FDA-approved active Small molecule

Naloxone reverses opioid overdose by blocking opioid receptors, while docusate softens stool to prevent opioid-induced constipation.

Naloxone reverses opioid overdose by blocking opioid receptors, while docusate softens stool to prevent opioid-induced constipation. Used for Opioid overdose reversal and prevention of opioid-induced constipation in patients on chronic opioid therapy.

At a glance

Generic name	Naloxone and Docusate
Also known as	Narcan, Colace
Sponsor	CAMC Health System
Drug class	Opioid antagonist + stool softener combination
Target	Opioid receptors (mu, delta, kappa) for naloxone; intestinal fluid secretion for docusate
Modality	Small molecule
Therapeutic area	Addiction Medicine / Pain Management
Phase	FDA-approved

Mechanism of action

Naloxone is a competitive opioid receptor antagonist that rapidly displaces opioids from mu, delta, and kappa receptors, reversing respiratory depression and overdose effects. Docusate is a stool softener that reduces water loss from stool and increases intestinal fluid secretion, addressing the constipation commonly caused by chronic opioid use. This combination product is designed to mitigate both acute overdose risk and chronic opioid side effects.

Approved indications

Opioid overdose reversal and prevention of opioid-induced constipation in patients on chronic opioid therapy

Common side effects

Withdrawal symptoms (naloxone)
Abdominal cramping (docusate)
Diarrhea (docusate)
Nausea

Key clinical trials

Enteral Naloxone Versus a Traditional Bowel Regimen for the Prevention of Opioid Induced Constipation in Trauma Patients (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Naloxone and Docusate CI brief — competitive landscape report
Naloxone and Docusate updates RSS · CI watch RSS
CAMC Health System portfolio CI